ArticleFrontiers in medicine2025
Global, regional, and national trends in DALYs for blindness and vision loss in teenagers and young adults, 1990-2019: an age-period-cohort analysis based on the Global Burden of Disease Study 2019.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To analyze temporal trends in disability-adjusted life years (DALYs) associated with blindness and vision loss in teenagers and young adults at global, regional, and national levels between 1990 and 2019, with particular attention to age, period, and birth cohort. Methods: Estimates were derived from the Global Burden of Disease Study 2019. An age-period-cohort (APC) model was adopted to estimate overall annual percentage changes in DALYs (net drift), annual percentage changes in DALYs within age groups (local drift), fitted longitudinal age-specific rates adjusted for period deviations (age effects), and period- and birth cohort-relative risks (period/cohort effects) between 1990 and 2019. This facilitated the identification of disparities and treatment gaps in eye care. Results: In 2019, the global number of DALYs associated with blindness and vision loss in teenagers and young adults was 2085.40 thousand (95% UI: 1340.56 to 3074.23). Among the 204 countries and territories, 40 had DALYs of at least 10,000, with the top five countries (India, China, Brazil, Indonesia, and Pakistan) being responsible for 48% of DALYs globally. The APC model estimated a global net drift at -0.43% (95% CI: -0.45% to -0.42%) per year, ranging from -0.92% (95% CI: -0.94% to -0.91%) in low-middle socio-demographic Index (SDI) regions to -0.03% (95% CI: -0.07% to -0.0005%) in high SDI regions. As reflected by local drift, the DALYs had decreasing trends across all age groups, except in high SDI countries. Age effects illustrated similar patterns across different SDI regions, with risk increasing with age. High SDI region showed generally higher period risks over time, whereas others showed more favorable period risks. High SDI regions presented worsening risks of DALYs, while other regions indicated improving trends of DALYs in successive birth cohorts. Conclusion: Although an overall favorable trend of DALYs related to blindness and vision loss in teenagers and young adults was observed globally over the past three decades, unfavorable period and cohort effects were found in many countries, raising questions about the adequacy of their eye care across all age groups. Improvements in prevention, treatment, and rehabilitation programs related to blindness and vision loss in teenagers and young adults could reduce the risk for successively younger birth cohorts and for all age groups over time.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.